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Abstract
UTILITY OF APPARENT DIFFUSION COEFFICIENTS IN THE EVALUATION OF PRIMARY
CENTRAL NERVOUS SYSTEM LYMPHOMA.
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The characterization of primary central nervous system lymphoma (PCNSL) via noninvasive
imaging modalities is essential for early diagnosis and differentiation from other brain lesions.
Diffusion-weighted magnetic resonance imaging (DW-MRI), in which intensity of image contrast
reflects diffusion of water molecules by Brownian motion, offers additional information beyond that
obtained from conventional MRI. In this retrospective study from two institutions, quantitative region of
interest (ROI) analysis was performed using parametric apparent diffusion coefficient (ADC) maps in
immunocompetent patients with newly diagnosed PCNSL prior to corticosteroid use or other therapy.
Mean ADC values and ratios were calculated for PCNSL lesions, peritumoral edema, and
contralateral normal white matter. Quantitative DW-MRI analysis (n=12) revealed significant intergroup variance between the mean ADC of lesion, peritumoral region, and normal white matter. Tukey
post-hoc comparison of the three groups indicate that the mean ADC of the peritumoral region is
significantly different (p<0.05) from mean ADC of the lesion and normal white matter, while
differences between mean ADC of the lesion and normal white matter were not statistically
significant. A comprehensive review of prior investigations reporting ADC values in evaluation of
PCNSL was also conducted. We found that restricted diffusion is a consistent imaging finding in
immunocompetent PCNSL patients and a reliable surrogate marker of tumor cellularity; however, the
ranges of ADC values reported for PCNSL varied between studies and also overlapped with ADC
ranges reported for other brain tumors. Given the observed variability in ADC values, it is essential to
consider DW-MRI data as an adjunct diagnostic tool interpretable only in the context of clinical
presentation and conventional MRI data. Further prospective investigation enrolling patients prior to
corticosteroid therapy will be necessary to obtain standardized pre-treatment ADC values.
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Introduction
Primary central nervous system lymphoma (PCNSL) is an aggressive
extranodal non-Hodgkin (NHL) lymphoma that targets brain, vitreous body and optic
nerves, leptomeninges, and spinal cord. (1-2) PCNSL accounts for approximately
2.4% of all primary CNS neoplasms by most recent estimates. (3) The incidence of
PCNSL increased approximately threefold in the 1980s and early 1990s, with the
rate of increase levelling off since then. (4-5) Individuals with congenital or acquired
immunodeficiency such as HIV or immunosuppressive therapy after an organ
transplant are predisposed to developing PCNSL, and it is believed that the
reduction in rate of increase of PCNSL incidence is at least partially attributable to
the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s. (5)
Nevertheless, incidence continues rise in both immunocompetent and
immuncompromised populations, across all age groups and in both men and
women. (6)
The clinical history of patients with PCNSL is variable. Most commonly,
patients present with signs of a focal mass lesion, including evidence of increased
intracranial pressure, seizures (more often in patients with AIDS), disturbances of
vision, confusion, lethargy, memory loss, and neuropsychiatric manifestations. (7)
Vague or unusual presenting complaints are also possible, e.g. a recent case report
of fever of unknown origin as the sole presenting manifestation, (8) or
panhypopituitarism and diabetes insipidus due to bilateral hypothalamic involvement.
(9) A neurologic prodrome is sometimes seen up to years prior to diagnosis, which
can include chronic vitritis (10) or multiple sclerosis. (11,12,13) Demyelinating
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“sentinel” lesions that recede spontaneously up to months/years before the
development of PCNSL have also been reported. (14-15) Whether these disorders
reflect an early stage of malignancy heralding PCNSL or atypical polyclonal
lymphoproliferations remains unclear. So-called “B” symptoms (fever, weight loss,
night sweats) common in other forms of NHL are seldom seen except in the rare
case of systemic dissemination.
For patients who present with acute symptoms of brain tumor, non-contrast
computed tomography (CT) of the head is the initial test of choice, primarily as a
screening tool to rule out immediately life-threatening intracranial pathology such as
a herniation or bleed. (16) However, due to the poor soft tissue contrast of head CT,
this imaging modality is not effective at discriminating subtle non-enhancing
parenchymal changes. (17) Given the additional ionizing radiation exposure and the
risk of contrast-induced hypersensitivity, head CT is reserved for initial acute
evaluation due to its wide availability, speed, and relatively low cost.
For further evaluation of patients with suspected brain tumor, the most
sensitive and specific diagnostic imaging modality is gadolinium contrast-enhanced
magnetic resonance imaging (MRI). (2) Its advantages are numerous: superior
anatomical detail, less risk of intolerance with gadolinium vs. iodinated contrast, no
ionizing radiation, and flexible acquisition in multiple planes. The standard protocol
includes contrast-enhanced T1 and fluid attenuated inversion recovery (FLAIR)
sequences; T1 with contrast is well-suited for evaluating disruption of the blood-brain
barrier with subsequent leakage of gadolinium, while FLAIR (a T2-weighted image in
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which free water is attenuated) is excellent at identifying peritumoral edema and
extent of tumor infiltration. (16,18)
Using these conventional MRI sequences, PCNSL typically presents in
immunocompetent patients as homogenously enhancing solitary or multiple lesions,
often in a periventricular location with spread along white matter tracts producing
mild edema or mass effect. (19,20,21) Lesions are hypointense or hyperintense on
T1-weighted images and roughly 40% are hyperintense T2-weighted signal by
recent estimates. (22) However, in immunocompromised individuals T2
hyperintensity is more common, which has been show to correlate histologically with
degree of intratumoral necrosis. (23) FLAIR sequence will demonstrate extensive
perifocal edema with nonenhancing tumor area. In terms of distribution, a recent
series of 100 immunocompetent PCNSL cases revealed lesions in cerebral
hemisphere (38%), thalamus/basal ganglia (16%), corpus callosum (14%),
periventricular region (12%), and cerebellum (9%). (24) Spinal cord or brainstem
involvement, meningeal or ventricular enhancement, calcification and hemorrhage
were uncommon.
The pattern of enhancement in PCNSL is variable, particularly in HIV/AIDS
patients or other immunocompromised individuals in which multiple lesions and rim
enhancement surrounding zones of central necrosis are more common (19). This
creates a diagnostic dilemma in distinguishing PCNSL from another common AIDSassociated space-occupying lesion, CNS toxoplasmosis, which has a similar rimenhancing appearance on MRI. (25) Diagnosis is further complicated by the empiric
use of corticosteroids in the patient population, which can significantly alter the
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appearance of PCNSL lesions by reducing contrast enhancement and brain edema
and altering cellular morphology through a direct lymphocytotoxic effect. (26)
Given these diagnostic challenges, there is great interest in utilizing other
noninvasive imaging modalities and/or biomarkers in order to better characterize
PCNSL and differentiate it from other tumors. One such modality is diffusionweighted MR imaging (DWI), in which intensity of image voxels reflects microscopic
diffusion of water molecules in tissues by stochastic (Brownian) motion. (27) A brief
technical review of DWI will now be presented to provide a theoretical framework for
discussion of its clinical applications and rationale for use in PCNSL.
Basic Principles of Molecular Diffusion and Diffusion-Weighted Imaging
First described by Einstein in 1905, (28) the principle of Brownian motion
states that molecules in a fluid medium diffuse randomly as a result of the thermal
energy carried by those molecules. (27) Assuming a homogeneous medium of “free
water,” diffusion follows a three-dimensional Gaussian distribution with a variance !2
= 2 * D * t where t = time allowed for diffusion and D = diffusion coefficient, which
reflects size of molecules, temperature, and viscosity of a medium. (29) Biological
tissues are far from homogeneous, however, and present obstacles to diffusion
(cellular membranes, organelles, etc.) that result in anisotropic diffusion in a nonGaussian pattern, particularly as diffusion distance increases. Diffusion MRI
provides insight into microscopic tissue structure – and perturbations in that
structure caused by pathologic states – by non-invasively recording diffusion of
water molecules in vivo.
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In conventional MRI techniques, a homogenous magnetic field is applied to
stimulate precession of water hydrogen nuclei (protons) around an axis parallel to
the direction of the magnetic field. The key difference of DWI is that a “dephasing”
pulse field sequence consisting of two symmetrical gradient pulses is applied to
introduce variance in magnetic strength. As early as 1950, Hahn discovered that in
the presence of a heterogeneous magnetic field, protons spin so as to reduce signal
intensity. (30) Precession rate of protons varies proportionally to magnet strength, in
the same way that the precession rate of a gyroscope depends on the force of
gravity. (31) Applying a pulsed field gradient in DWI thus alters the rate of
precession of protons and leads to phase dispersion of their transverse
magnetizations (xy component of net magnetization vector), which results in signal
loss. (32) A “rephasing” radiofrequency (RF) pulse identical in direction but opposite
in magnitude is applied to refocus this dispersion in between the gradient pulses.
However, spins that have moved along the gradient axis in the interval between the
application of the first and second gradient pulses will not be reset to their initial
state; rather, a phase shift will occur relative to the hydrogen protons of immobile
water molecules. This manifests as signal loss because the overall vectorial sum of
the spin phases in a dispersed state is less than if they were all precessing
synchronously.
The amount of signal loss can be predicted with the following equation
originally described by Stejskal and Tanner in 1965:
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(33)
where S is signal after pulsed field gradient application; S0 is signal intensity prior to
gradient application; " is a constant termed the gyromagnetic ratio, representing the
ratio of a proton nuclear magnetic dipole moment to its angular momentum—when
multiplied by the magnetic field strength in Tesla (T), this represents the rate of
proton nuclear precession known as the Larmor frequency; (34) G and # are
strength and duration of gradient pulse, respectively; $ is time between application
of two pulses; D is the diffusion coefficient; and b-value is a summary “diffusionsensitizing factor” reflecting the overall strength of diffusion weighting. (33) A
summary of the diffusion MR pulsed field gradient incorporated into a representative
spin-echo sequence is provided in Figure 1.
According to Stejskal and Tanner’s equation, four major variables can impact
DWI signal intensity: time between application of the two gradients, strength and
duration of gradient pulse applied, and the diffusion coefficient. It makes sense
intuitively that signal intensity decreases as the amount of time between application
of the two gradient pulses increases, because water molecules are allowed more
time to diffuse; consequently, the phase refocusing pulse is less exact due to a
larger displacement distribution of spins, which translates as signal attenuation.
Signal intensity also varies proportionally with the strength and duration of the
gradient pulse applied. These effects reflecting diffusion sensitization are
summarized by the b-value. Finally, signal intensity varies according to the intrinsic
rate of diffusion in tissues represented mathematically by the diffusion constant.
Simply stated, faster diffusion results in larger phase shifts and greater signal loss.
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Diffusion weighting can be used with many different imaging sequences but
echo planar imaging (EPI) is often utilized because acquisition is rapid (typically in a
single acquisition period of 25-100 msec) (35) and macroscopic motion artifacts (e.g.
“ghosting,” “blurring”) due to patient motion, breathing, or pulsatile blood flow are
consequently minimized. (36) Motion is a particular issue for diffusion MRI because
the microscopic motion of interest that induces phase shifts in spins can easily be
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confounded by macroscopic motion of the type described above. This would not
necessarily be an issue if all spins experienced the same approximate displacement,
but because each sequence is repeated several times, the aberrant macroscopic
motion pattern is present in some runs but not others, resulting in the “ghosting”
artifact. As is often unfortunately the case, however, the solution to this problem
introduces problems all its own— EPI itself is prone to artifacts such as chemical
shift and eddy currents produced when gradient pulses are switched on and off, and
the magnetic field gradient generates a current through the conducting surfaces of
the MRI scanner. (36)
Another important caveat is that diffusion-weighted images do not provide the
most accurate indicator of the diffusion coefficient. This is because visual contrast on
DWI is not solely b-value dependent, but also reflective of other weighting
mechanisms (e.g. T2 relaxation). (31) In fact, when b-value = 0, the image sequence
is simply that of a T2-weighted sequence which only reflects diffusion weighting
once a pulsed field gradient is applied. A classic example of a problem in
interpretation stemming from this issue is “T2 shine through” in which a
hyperintensity on DWI may reflect T2 weighting and cannot be differentiated from
true diffusion restriction. (36) In order to characterize water diffusion free of similar
confounders, it was proposed that the physical diffusion coefficient be replaced by a
statistical parameter, the apparent diffusion coefficient (ADC). (37) To calculate
ADC, b-values from at least two acquisitions (typically b=0 and b=1000 s/mm^2) are
plotted logarithmically against signal intensity, and the slope (i.e, rate of signal
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decay) is deemed the diffusion constant, which can be mapped pixel-by-pixel to
create a parametric ADC image map (Figure 2).
As a statistical parameter, ADC depends not only on intrinsic physical
diffusion properties but also on other technical features such as diffusion time and
voxel size; additionally, the scaling from voxels (usually on the order of a few cubic
millimeters) results in an averaging or smoothing effect (36-38). How, then, do
scientists and clinicians rationalize the fact that different portions within a single
voxel may have significantly different diffusion properties? The parameterization and
averaging has been likened to the efforts of meteorologists to describe natural
atmospheric processes on a scale much larger than the local physical forces being
approximated, forces that technical limitations prevent us from accurately
measuring, whether it be diffusion in tissue microarchitecture or the microphysics of
thunderstorms. (38) The underlying assumption is that as long as one can make
reliable and informed predictions based on the data, the parameter need not reflect
the physical environment with complete accuracy in order to remain a useful clinical
tool for diagnostic and/or treatment decisions.
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Clinical Applications of Diffusion-Weighted Imaging
In the clinical setting, DWI has proven most useful in distinguishing between
cytotoxic and vasogenic edema in cerebral ischemia. (39, 40) In vasogenic edema,
tight endothelial junctions comprising the blood-brain-barrier (BBB) are disrupted,
resulting in variable signal intensity on DWI and higher ADC due to spread of protein
and fluids into the extracellular space. (41) Conversely, restricted diffusion with DWI
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hyperintensity and low ADC is observed in cytotoxic edema, reflecting a loss of
extracellular fluid with commensurate swelling of intracellular compartments due to
cellular retention of sodium and water from ATP depletion and consequent failure of
the Na+/K + ATPase. (42,43) Cytotoxic edema is most characteristic of early acute
ischemia, with changes in ADC occurring with minutes after onset, but can also be
seen with various intoxications, encephalopathies, hypoglycemia, status epilepticus,
or any other non-ischemic cause of deranged cellular metabolism. (44) Conversely,
T2-weighted images will remain normal for several hours, eventually displaying an
increase in intensity due to vasogenic edema. (45) ADC values in acute stroke reach
their nadir by 24 hours and persist for 1-2 weeks, and although “cytotoxic edema” is
repeatedly attributed as the explanation for persistent changes on DWI, (46) several
researchers have suggested there are likely to be other mechanisms underlying
ADC change that have not yet been elucidated. (47) Nevertheless, DWI has proven
very sensitive (although some lacunar infarcts may not be detected) and reasonably
specific in early detection of acute ischemic stroke during the crucial ‘window of
opportunity’ for therapy. (48)
In recent years, research into clinical applications of DWI has greatly
expanded in an attempt to better characterize neurologic disorders other than acute
stroke. (49) For example, movement disorders including Parkinson’s disease,
progressive supranuclear palsy, and multiple system atrophy (50,51) have been
studied with a ROI-based approach that readily differentiated some of these
conditions on the basis of DWI findings. Diffusion MRI has also been employed in
studying features of Alzheimer’s Disease (AD) and non AD-type dementias, (52)
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early diagnosis of Creutzfeld-Jakob disease, (53) multiple sclerosis, (54) herpes
encephalitis, (55) and epilepsy (including status epilepticus, interictal phases, and
single seizures). (56) In addition, DWI has been used to differentiate arachnoid and
epidermoid cyst (57) and subtypes of brain abscesses, including differentiation of
pyogenic abscess from necrotic tumor. (58) This list is far from comprehensive, as
an explosion of clinical literature utilizing this technique has occurred in a relatively
short period of time, reflecting the tremendous potential of diffusion imaging for use
in the clinical setting.
The literature concerning DWI in diagnostic evaluation of patients with brain
tumors has increased particularly rapidly; several recent studies have attempted to
correlate ADC with cellularity or grade of various tumors, assess infiltration into
peritumoral edema, or differentiate among tumors that can otherwise appear similar
using conventional MR techniques (e.g. PCNSL, glioblastoma multiforme, anaplastic
astrocytoma, metastases). (59) Many early studies, however, were not encouraging;
for example, a study aimed at distinguishing between tumor tissue and peritumoral
edema in gliomas found no ability to differentiate on the basis of absolute ADC
values or ADC ratios. (60) Another study found that ADC was helpful in grading of
malignant brain tumors in a sample of 33 low-grade (23 astrocytomas, 10
oligodendogliomas) and 40 high-grade (25 metastases, 15 high-grade astrocytomas)
neoplasms, but was unhelpful in differentiation among them. (61) In a 2001 study
examining 56 patients with the three most common types of intracranial neoplasms
(gliomas, metastases, and meningiomas), too much variation existed within each
group to reliably differentiate among them on the basis of either DWI or ADC maps.
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(62) Furthermore, the authors were unable to successfully use either DWI or ADC to
assess tumor infiltration or differentiate infiltration from perifocal edema, which
contradicted a previous report. (63) Another 2001 study found considerable overlap
in ADC values and could not separate tumor from surrounding edema in a small
sample of patients with high-grade cerebral glioma. (64) A third 2001 study found no
advantage of DWI in evaluating tumor extension in a sample of patients with
gliomas, metastases, meningioma, and abscess. (65)
This led a member of the editorial board of the neuroradiology journal in
which several of the above articles were published to state in 2001 that “the bloom
[is] off the rose” with respect to the use of DWI in evaluation of brain tumors: “There
is a natural history for new diagnostic tests. The initial results are amazing, the
praise overwhelming. The test is viewed as having almost magical qualities. After a
while, reality sets in. The initial enthusiasm wanes as experience accumulates. This
is where we are now with diffusion-weighted imaging.” (66) Yet, the author
concluded that DWI was nevertheless a potentially valuable tool, particularly when
studies utilized a quantitative analysis of specified ADC regions of interest, as a
more sensitive way of revealing significant abnormalities that may not be readily
apparent simply by looking at a diffusion-weighted image or ADC map.
A small number of studies have begun to characterize DWI findings in
patients with PCNSL, (67,68) attempt to differentiate between PCNSL and other
tumors on the basis of DWI, (69,70,71,72,73,74) and even utilize ADC as a predictor
of clinical outcome and response to therapy. (75) Yet, the body of literature available
for comparison of findings in PCSNL remains relatively small, as does the sample
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size in individual studies. Additionally, studies utilizing DWI in the characterization of
PCSNL continue to appear with findings that contradict prior reports; as recent as
2009, Server et al. found no significant difference between malignant gliomas and
PCSNL on the basis of DWI. (76) Is the “bloom off the rose” in the case of diffusionweighted imaging in PCNSL, or will ADC be established in time as a surrogate
marker of cellularity to characterize and differentiate among tumors, and perhaps
even predict therapeutic response? Given the need for additional clarity in the
relatively meager and sometimes conflicting literature, and as the incidence of
PCNSL continues to rise in the population, we conducted a retrospective study
utilizing a comprehensive neuroimaging protocol including DWI and quantitative
ADC region of interest analysis to better characterize the MRI appearance of this
disease.
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Statement of Purpose:
The purpose of this investigation was to identify and characterize the earliest
DW-MRI findings in patients with PCNSL prior to corticosteroid use or other therapy.
Quantitative region of interest analysis was performed using parametric ADC maps.
ADC values derived from this study were then compared to measurements from
other studies via a comprehensive review of prior investigations utilizing DWI in the
evaluation of PCNSL. The hypothesis was that restricted diffusion is a reliable
marker of increased tumor cellularity in PCNSL, and that ADC values may be useful
to differentiate PCNSL from other intracranial lesions.
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Methods
Disclosure statement: All MRI protocols were performed by clinicians at Yale-New
Haven Hospital and Massachusetts General Hospital. Study was conceived and
identification of patient cohort was performed by J.M.B., S.B., E.H., and F.H.H.
Quantitative DW-MRI region of interest analysis and selection, abstraction, and
review of prior literature for comparison with the measurements derived in this thesis
was performed by J.W.G. with R.K.F. as primary advisor.
This project was approved by the Human Investigation Committee at Yale University
School of Medicine and the Internal Review Board at the Massachusetts General
Hospital.

Subjects
Three databases were accessed to gather subjects: the Connecticut Cancer
Registry, the Yale School of Medicine (New Haven, CT) Brain Tumor Center
database, and the Massachusetts General Hospital (Boston, MA) Brain Tumor
Center database. The dates evaluated were between January 1982 and July 2007
for the Connecticut and Yale databases, and between January 2000 and June 2007
for the MGH database. Patients with PCNSL were included only if they had a
histopathologically confirmed diagnosis. Exclusion criteria included congenital or
acquired immunodeficiency (e.g., HIV), lymphoma without cerebral involvement
(e.g., primary intraocular lymphoma), or patients where insufficient clinical
information was available to ascertain appropriateness for inclusion (e.g., missing
histopathology report or imaging data at diagnosis).
137 immunocompetent patients with PCNSL were initially identified, including
45 cases from Yale and 95 cases from MGH. Of these, 56 cases were excluded due
to insufficient data or lack of access to imaging performed at the time of initial
diagnosis. In addition, nine cases were primary intraocular lymphoma without CNS
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spread, leaving a total of 72 cases meeting entry criteria. Of these, sixteen cases
with DWI data and ADC maps available in PACS for region of interest analysis were
identified. Four were excluded due to insufficient data, leaving a final cohort of 12
cases for quantitative DW-MRI analysis. The study cohort includes 9 men and 3
women with a median age of 48.5 years (range 14-73), including one pediatric case
aged 14 at time of diagnosis.
MR Imaging
This study was retrospective in nature, so MRI protocols and timing are not
standardized among patients. A 1.5T MR Imaging unit was used at both Yale-New
Haven Hospital and MGH. T1-weighted spin-echo images were obtained in axial,
coronal, and sagittal planes with the following parameters: repetition time [TR]=600
ms; echo time [TE]=20 ms; number of excitations=1, and long-TR dual-echo axial
sequences (2500/30.9/1). Other imaging parameters include: field of view=21 cm,
256x192 matrix slice thickness 5 mm with spacing of 0-2 mm. T1-weighted axial
images were obtained before and after intravenous administration of gadopentate
dimeglumine contrast medium (0.1 mmol/kg). ADC maps were generated based on
diffusion-weighted echo planar sequences. Six high b-value images (1000 mm%/s)
and one low b-value images (3 mm%/s) were acquired for each of 23 axial slices. The
following parameters were used: TR=10 s, TE=104 ms, diffusion encoding
gradients=45 ms, 128x128 matrix, field of view, 24.5 mm slice thickness, 1mm
spacing, one signal average.
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Imaging Analysis
Postprocessing of apparent diffusion coefficient (ADC) maps and values
occurred on a Siemens workstation (Siemens Medical Solutions, USA). DWI images
and ADC maps were aligned with contrast-enhanced T1-weighted and FLAIR
images corresponding to the same section level. Patients were retrieved from PACS
using a combination of date and medical record number, and all images retrieved
were rendered anonymous and free of any patient identifiers. ROIs were drawn from
the solid enhancing region of tumor, peritumoral edema, and contralateral normalappearing white matter (Figure 1) using a circular pixel lens tool available in the
workstation. All ROIs drawn were approved by a neuroradiologist blinded to all
information other than diagnosis (R.K.F.). ROI areas ranged between 0.47-0.78 cm2
and were drawn to avoid necrotic or hemorrhagic areas. Values for ADC mean,
minimum, and standard deviation were calculated. Ratios (ADC of tumor focus to
ADC of peritumoral region; ADC of tumor focus to ADC of contralateral normal white
matter) were also calculated. Inter-group variance in mean ADC values between
ROI groups was assessed using one-way Analysis of Variance (ANOVA). All ADC
values are reported as 100 x 10^-6 mm2/s. Pairwise post-hoc comparison of mean
ADC values between groups was performed using Tukey’s HSD test at the p<0.01
level of significance.
Literature selection
Prior studies utilizing DWI in the study of PCNSL were chosen by searching
MEDLINE, Web of Science, and Google Scholar for articles listed between 1992
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(when DWI was first used in the early diagnosis of cerebral ischemia) and 2010.
Relevant search terms were used, including any combination of “diffusion-weighted
imaging,” “diffusion imaging,” “DWI,” “DW-MRI,” or “diffusion MR imaging” with
“primary CNS lymphoma,” “central nervous system lymphoma,” “primary lymphoma
of the central nervous system,” “brain lymphomas,” “cerebral lymphoma,” or
“PCNSL”. After scanning titles and abstracts, relevant full articles were reviewed to
select those reporting original research using quantitative ADC/DWI measurements.
In addition to these measurements, the following information was retrieved for each
study: authors, year of publication, number of cases, average age of patients,
stratification of patient groups, and methods of ROI drawing and ADC calculation.

Figure 1: Apparent diffusion coefficient (ADC) map (a) and axial gadolinium
contrast-enhanced T1-weighted MR image (b) at same level in case of primary
CNS lymphoma. ROIs are placed centrally in the core of the lesion, in the
adjacent peritumoral edema, and in contralateral normal white matter.

(a)

(b)
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Results
ROI analysis was performed for cases with DWI and ADC maps available
(n=12), an example of which is illustrated in Figure 2. The mean ADC and range of
the enhancing portion of PCNSL lesions was 888 +/- 137 x10-6 and 609-1065 x10^-6
mm2/s, respectively. The minimum ADC and range of the enhancing portion of lesion
was 704 +/-185 x10-6 and 326-947 x10-6 mm2/s, respectively. The mean ADC and
range of the peritumoral region was 1429 +/- 272 x10-6 and 1162-1934 x10-6 mm2/s,
while the mean ADC and range of contralateral normal-appearing white matter was
878 +/- 146 x10-6 and 578-1083 x10-6 mm2/s, respectively. The ADC ratio of the
enhancing portion of the lesion to surrounding perifocal edema was 0.64 +/-0.13,
while the ratio of the enhancing portion of lesion to contralateral normal-appearing
white matter was 1.12 +/-0.07.

One-way Analysis of Variance (ANOVA) revealed significant inter-group
variance between the mean ADC of lymphomas, peritumoral regions, and
contralateral normal white matter (F (2,33)=31.438, p<0.001). Tukey post-hoc
comparison of the three groups indicate that the mean ADC of the peritumoral lesion
is significantly different from the mean ADC of the lesion and normal white matter.
However, differences between mean ADC of lesion and normal white matter were
not statistically significant at p<0.01.

Our literature search for prior studies of DWI in PCNSL revealed 13 articles
that met eligibility criteria for comparison, describing a total of 133 separate patients
with lymphomas for which DWI/ADC quantitative measurements were recorded
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(Table 1). Ten out of thirteen reported ADC values of lymphoma lesions as means,
four studies reported ADC minimums, and two studies reported ADC medians. One
study provided data on 25th percentile ADC values and another reported ADC
maximums. Two out of thirteen did not provide complete information regarding
standard deviation of reported values, and three out of thirteen did not provide a
range of values. In two studies, range could only be approximated based on boxplot
data. Two out of thirteen reported ADC measurements from perilesional edema or
contralateral normal white matter; in one additional study, the mean ADC value for
normal white matter was approximated from the reported ADC ratio of lesion to
contralateral normal white matter. This ratio was reported in five out of thirteen
studies. However, only one study prior to ours reported a ratio of lesion to
surrounding peritumoral edema. Most studies reported data from immunocompetent
patients or did not specify patient immune status; however, one study (Camacho et
al.) was strictly limited to AIDS patients, another (Kitis et al.) stratified ADC values
into immunocompetent and immunocompromised patient groups, and a third
(Zacharia et al.) included both immunocompetent and immunocompromised
individuals but stratified ADC reporting based on pattern of enhancement rather than
immune status. Additional details of individual studies are addressed in the
Discussion.
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Table 1: Comparison of Diffusion-W eighted Imaging Findings in PCNSL.
All ADC
values
reported
-6
(x10^
2
mm /s).

N

ADClesion

Range

ADC perilesion

Our Data

12

888+/-137
(mean)

609-1065

1429+/-272
(mean)

Guo et al., 2002

11

870+/-270
(mean)

n/a

Camacho et al.,
2003

4

930(SD n/a)
(mean)

8

ADC normal

Ratio ADC

Ratio ADC

lesion/normal

lesion/perilesion

878+/-146
(mean)

1.02+/-0.07

0.64+/-0.13

n/a

750 +/- 40
(mean)

1.15+/-0.33

n/a

670-1200

n/a

n/a

1.14+/-0.25

n/a

540+/-100
(min)
550+/-120
(min)
n/a

350-670

n/a

n/a

n/a

n/a

(AIDS patients)

Kitis et al., 2005
Immunocompetent

6

Immunocompromised

2

n/a
n/a

Yamasaki et al.,
2005

8

725+/-192
(mean)

504-1067

n/a

n/a

n/a

n/a

Calli et al., 2006

8

510 +/- 90
(min)

~400-650

n/a

n/a

n/a

n/a

Reiche et al.,
2007

4

757
(median)

602-860

1567
(median)

n/a

n/a

n/a

Al-Okaili et al.,
2007

12

860+/- 220
(mean)
990
(median)

370-1100

n/a

n/a

n/a

n/a

Toh et al., 2008

10

630+/-155
(mean)

371-806

n/a

752 +/-86
(mean)

0.83+/-0.14

n/a

Akter et al., 2008
DWIHyperintense

16

780+/-170

n/a

n/a

n/a

n/a

n/a

(9)

690+/-140

Partial
Hyperintense

(4)

840+/-110

Isointense

(3)

960+-210
(mean)

Zacharia et al.,
2008

20

n/a

n/a

n/a

n/a

Homo/Heterogeneous

(15)

650+/- 43

570-720

Ring enhancing
- (Lesion Periphery)

(5)

720+/-41

650-800
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-

(Lesion Center)

1140+/-20

1060-1210

Post-Treatment

(7)

n/a
(mean)

860-1140

Horger et al.
2009

9

710+/-130
(mean)

~500-900

n/a

n/a

0.93+/-0.19

n/a

Server et al.,
2009

5

732+/-170
(mean)
648+/-155
(min)

n/a

1.59+/-0.27
(mean)
1.49+/-0.24
(min)

~711
(mean,
approx.)

1.03+/-0.24
(mean)
1.03+/-0.26
(min)

0.46+/-0.08
(mean)
0.43+/-0.08
(min)

Barajas et al.,
2010

18

830(SD n/a)
(mean)
377(SD n/a)
(min)

636-1016
(mean)
167-614
(min)

n/a

n/a

n/a

n/a

(7)

757+/-96
(mean)
244+/-84
(min)
876 +/-74
(mean)
462+/-98
(min)

Response
Groups
- Primary
Refractory

- Clinical
Response

(11)
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Figure 2: Typical DWI findings in PCNSL. Diffusion-weighted imaging (A)
shows hyperintensity corresponding to a right occipital mass, while ADC map
(B) shows low signal consistent with restricted diffusion. Gadolinium contrastenhanced T1-weighted imaging shows strong homogeneous enhancement in
the mass (C), which can be seen on FLAIR (D) to invade the splenium of
corpus callosum and right lateral ventricle.

A

B

C

D
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Discussion
A small number of studies have attempted to characterize DWI findings in
PCNSL, (65-68, 77) differentiate between PCNSL and similarly appearing tumors,
(69-74) or predict response to therapy and clinical outcome. (75) DWI is thought to
provide information about tumor cellularity or grade because water diffusion
correlates highly with the ratio of extracellular to intracellular space, (33,41) with
greater diffusion expected in an extracellular medium. (37) A highly cellular tumor
such as PCNSL serves as a significant barrier to water diffusion by decreasing the
volume and increasing the tortuosity of the extracellular space, which is (in theory)
reflected as a relative decrease in ADC value and increased signal on DWI
compared to less cellular tumors.
Although several groups have provided data in support of restricted diffusion
as a consistent finding on DWI in PCNSL, to date there has not been a
comprehensive review of quantitative methods and measurements among
investigators. We presented the ADC values derived in our study with a summary of
findings from prior work in Table 1. The earliest quantitative study using ADC values
in PCNSL was a 2002 retrospective series of 19 brain lymphomas in 11 patients by
Guo et al., which used ADC ratios of tumor to normal-appearing regions in a small
cohort of patients with either lymphoma or astrocytoma. (69) Sixteen of nineteen
lesions appeared hyperintense on DWI and iso- to mildly hypointense on ADC
signal; additionally, an inverse correlation between diffusion and cellularity was
reported based on calculation of nuclear-to-cytoplasmic (N/C) ratios in histologic
samples. However, the correlation between ADC values and N/C ratios was
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relatively modest (r=-0.46). A later study confirmed an inverse correlation between
mean ADC and cellular density of similar magnitude (r=-0.54). (75) This suggests
that factors other than tumor cellularity are at play in determining ADC values, which
may include degenerative changes such as hemorrhage or abscess and local effects
due to expression patterns of hydrophilic components of the extracellular matrix. (78)
PCNSL in immunocompetent patients is typically a non-necrotic, homogeneousappearing tumor lacking these confounding degenerative changes; thus, it is
believed that DWI represents a potentially useful and specific diagnostic tool for this
disease.

In a similar series of 16 patients with PCNSL, thirteen (80%) were
hyperintense or partially hyperintense on DWI, which corresponded to lower overall
mean ADC values than isointense lesions; however, significant overlap existed
between all three groups. (79) Zacharia et al. studied 20 patients comprising both
immunocompetent and immunocompromised as well as pre- and post- treatment
cases, finding areas of restricted diffusion in 90% (18/20) of pretreatment scans. (67)
The ADC range was higher with significant variability in both post-treatment and
immunocompromised individuals, presumably reflecting low cellularity as a
consequence of increased necrosis and partial volume effect due to decreased
lesion size. Another issue was highlighted in Reiche et al.’s DWI study of four
PCNSL cases, one of which displayed an absent enhancement pattern that delayed
time to diagnosis and biopsy. (68) This pattern of enhancement is a rare but known
(80) presentation of PCNSL and underscores the potential of DWI—which showed
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lesions in this case to be hyperintense with low ADC suggestive of a hypercellular
neoplasm—to provide clues in difficult diagnostic situations.
A number of investigators have attempted to use DWI to distinguish PCNSL
from other lesions that appear similar on conventional MRI (e.g. glioblastoma
multiforme, anaplastic astrocytoma, some highly cellular metastases). One such
study used minimum ADC values to differentiate low-grade gliomas from high-grade
gliomas, metastases, and lymphomas, observing consistently low ADC values for
the latter; however, this difference did not achieve statistical significance and the
range of lymphoma ADC values overlapped with those of high-grade gliomas. (81)
Server et al. also found no significant difference between malignant gliomas and
PCSNL with DWI. (76) A third group found no difference on the basis of either mean
ADC of enhancing tumor or ADC ratio of tumor to uninvolved white matter between
lymphoma and glioblastoma in a study restricted to invasion of the corpus callosum.
(72) However, echoing an earlier report by Guo et al., they did find a significant
difference on the basis of ADC values between lymphomas and astrocytomas. In
contrast to the prior studies, a report by Calli et al found a significant difference
between lymphomas and both GBMs and AAs on the basis of minimum ADC values.
(73) Similarly, Toh et al. and Yamasaki et al. found a significant difference between
PCNSL and GBM based on ADCs. (70-71) However, there was considerable
overlap in the range of values between groups in all three of these studies. This
conflicting evidence highlights the lack of clarity in the literature and the importance
of interpreting potentially variable ADCs in the context of a full clinical and MR
imaging evaluation.
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DW-MRI has also been used to evaluate select populations in which the
differential diagnosis of brain masses can be particularly challenging, such as
patients with AIDS. In these individuals, toxoplasmosis and PCNSL are the two most
common etiologies. The characteristic rim-enhancement and profound vasogenic
edema of infectious abscess is often difficult to distinguish from tumor in
immunocompromised hosts. Camacho et al. used ADC values to differentiate
PCNSL from toxoplasmosis in patients with AIDS, and although there was a
statistically significant difference between the two groups, there was again
considerable overlap in the range of ADC values. (82)
Overall, there is a demonstrated trend of either negative results or reports of
statistical significance belied by significant overlap between ADC values in the
literature regarding use of DWI in differential diagnosis of PCNSL. This is consistent
with several studies that have reported negative results attempting to use DWI or
ADC maps to differentiate between various tumors not including PCNSL, or between
tumor tissue and surrounding edema. (4,60-64) The range of values that we derived
with a patient population and methods similar to prior reports also overlap
significantly with reported range of ADCs for other tumors. Even for studies strictly
limited to characterization of PCNSL, there is substantial variation in the range of
ADC values reported. Among all studies, values ranged from 371-1200 x 10-6 mm2/s
for the solid enhancing portion of a PCNSL lesion, and mean values ranged from
650 – 930 x 10-6 mm2/s (Table 1). There is also a lack of consensus regarding which
DWI metrics are most informative—investigators have reported ADC values in terms
of means, medians, minimums, 25th percentiles, ratios, values for
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homogeneously/heterogeneously enhancing vs. ring-enhancing portions of lesions,
values for individual lesions vs. averages of regions from several lesions, and so
forth. While there is intrinsic appeal to a DWI region of interest method where one
can choose locations based on an a priori hypothesis about the relationship between
tumor cellularity and ADC, there are other complex underlying pathological
processes that influence the value obtained, thus rendering conclusions drawn from
these widely varying and overlapping ADC ranges tenuous. Future studies
comparing groups of tumors should establish firm “threshold” levels above or below
which lesions can be differentiated with near-100% accuracy, rather than report a
statistically significant difference between two overlapping ranges of values that are
of little clinical benefit out of context.
In addition to variance in how investigators choose to report ADC values and
heterogeneity of PCNSL appearance and presentation, several other limitations of
our study and the studies summarized in Table 1 account for the discrepant
evidence in the literature. Many conclusions are based on a very small sample size
(as few as 4 lesions), or with significant error in values reported (in the Guo et al.
series, the standard deviation of the mean ADC for PCNSL lesions was 31% of the
estimate itself). Variability is also introduced by using less than six b values in
generation of an ADC map, and many of these studies used such a technique
(although studies have shown that the error used by this method is small). (83) The
sampling method is also a significant potential source of confounding. This includes
error inherent to the subjective process of manually positioning regions relative to
affected anatomical structures, difference of opinion among investigators regarding
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whether areas of degeneration or necrosis or vascular territories should be included
or excluded from regions of interest, (84) “normal-appearing” tissue on MR imaging
actually representing underlying pathology and inappropriately being used as a
tissue reference, and errors inherent to faulty software co-registration of images.
Owing to the retrospective nature of these studies, some relevant images and
clinical information or cases may have been missed. Patients exposed to
corticosteroids or other conditions that could have altered the appearance of images
used in analysis may have also been included inappropriately. Large-scale
prospective studies in the future with strictly defined criteria for pre-treatment ADC
determination should serve to address some of these issues.
One other issue of note highlighted by our data is the lack of difference
between mean ADC of the enhancing portion of PCNSL lesions and ADC of
contralateral normal white matter. Less than half of prior studies measuring ADC
values for PCNSL reported ratios normalized against normal white matter (Table 1).
Although our absolute value for ADC of contralateral normal tissue is the highest
among the studies that have reported these values, our ratio of ADC (lesion/normal)
is in line with prior estimates, which have ranged from 0.83 to 1.15 with a standard
deviation between 0.07 and 0.33 (Table 1). That these estimates typically include a
possible ratio of 1 suggests little difference between the ADC of an enhancing
PCNSL lesion and uninvolved normal white matter, which is surprising given the
inverse relationship between cellularity and diffusion emphasized in the literature
and the dramatically restricted diffusion relative to normal tissue one might expect in
a highly cellular environment. This suggests that ADC measurements are not as
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highly correlated with cellularity as imagined, and subject to other biophysical forces
that remain poorly understood. One possibility may be related to the pathologic and
histologic features of PCNSL, which are remarkable in that neoplastic cells tend to
congregate in sheets along vascular channels. (85) It has been theorized that the
mechanism of PCNSL spread is through enlarged perivascular (Virchow-Robin)
spaces with infiltration of vessel walls. (86) This phenomenon may also predispose
to partial volume effects with entrapped interstitial fluid in perivascular regions or
vasogenic edema within lesions that could affect ADC values obtained. Additionally,
while the absolute ADC value may not be helpful in delineating between normal
white matter and PCNSL lesions, the ratio of lesion to perifocal edema highlighted a
consistent and significant difference in our series. Our values are consistent with the
one other study that reported this ratio (Table 1). Further research will be necessary
to determine if the values we obtained for this ratio are reasonably specific for
PCNSL.
Where does the future lie with regard to use of DWI in clinical evaluation of
PCNSL? Current research is aimed at investigating its use in predicting clinical
response and therapeutic outcome. In the past, DWI has been used to distinguish
tumor recurrence from radiation-induced necrosis (87-88) or postoperative changes
(89) and detect early response to therapy in brain tumors, (90-91) although
conflicting studies have shown both increased (92) and decreased (93) ADC in
response to treatment. Functional diffusion maps, in which voxel-by-voxel changes
in ADC measurements are tracked through serial DWI, have also been shown to
track tumor growth in gliomatosis cerebri (94) and predict treatment response in a
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variety of tumors (not including PCNSL). (95-96) Barajas et al. tested the hypothesis
that tumor cellular density in PCNSL as reflected by pre-treatment ADC values
within contrast-enhancing regions of tumor could be used to predict clinical outcome.
(75) Patients with 25th percentile ADC values <692 and minimum ADC values <384
x 10-6 mm2/s predicted disease refractoriness as measured by shorter progressionfree and overall survival, while those above those thresholds had a reduction in posttreatment ADC values and improved survival. (11) The authors state that the
reduction in ADC values in the “high ADC” group might be due to reduced
extracellular diffusion secondary to cellular swelling as a consequence of
responsiveness to chemotherapy. However, the distance between treatment
initiation and post-treatment imaging (up to several months) argues against this
hypothesis. Regardless, the evidence that ADC is able to serve as a surrogate
marker for therapeutic response is encouraging, and interest in post-treatment
surveillance imaging biomarkers should remain high as chemotherapeutic and
radiation therapy options advance and improve outcomes.
The future of PCNSL imaging research lies also in the use of more
sophisticated techniques. For example, diffusion is frequently anisotropic in the brain
while “basic” DWI only measures diffusion speed along one direction. By varying the
orientation of the MRI diffusion gradient along orthogonal directional axes,
differences in diffusion and image contrast can be observed. (97) This technique,
known as diffusion tensor imaging (DTI), is increasingly being used in the evaluation
and differential diagnosis of PCNSL with promising initial findings; for example,
fractional anisotropy (FA, an index of diffusion anisotropy that reflects the
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microarchitecture of CNS white matter fibers) was significantly lower in PCNSL vs.
GBM. (71, 98) Given that the directionality data in DTI could theoretically be applied
to provide structural information regarding unique features of localization/infiltration
of PCNSL lesions relative to white matter tracts, and that FA has been correlated
strongly with cellularity, (99) it is likely that the body of literature studying not only
DWI but also DTI in the evaluation of PCNSL will continue to expand.
Taken together, our results support restricted diffusion as a consistent DWI
finding in PCNSL, particularly as compared to peritumoral edema. This view is in
accord with prior studies that have demonstrated an inverse correlation between
ADC and cellularity of lesions. However, the reported strength of this relationship is
modest, presumably due to other factors affecting ADC measurements that, in
addition to methodological differences and other limitations of prior studies, account
for the variance of values reported in the literature. There is currently insufficient
evidence to advocate the use of ADC values as a definitive basis for differential
diagnosis of intraaxial brain masses, as the ranges of ADC values reported for
lymphoma frequently overlap with those of other tumors. However, in difficult
diagnostic situations where clinical information and conventional MR imaging data is
insufficient to render a diagnosis, use of DW-MRI may be helpful as an adjunct to
point the clinician in the right direction, as in the example of a rare non-enhancing
lymphoma lesion displaying restricted diffusion with a low ADC. Additionally, imaging
strategies that incorporate multiple techniques may represent a path forward; for
example, a recent study combined conventional MR imaging, perfusion MR imaging,
and proton MR spectroscopy to differentiate high-grade neoplasms and lymphoma
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from low-grade neoplasms and noncancerous lesions with an accuracy and
sensitivity of 85% and 84%. (74) Ultimately, there remains no substitute for clinical
judgment. Caution must be urged against overreliance upon quantitative
measurements when arriving at a final diagnosis, and such data should always be
interpreted in the context of the patient’s full clinical presentation.
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